InMed Pharmaceuticals Free Cash Flow (FCF) History (INM)
InMed Pharmaceuticals reported −$7.0M in free cash flow for fiscal 2024, an increase of $448,088 from the previous fiscal year, with a free cash flow margin of −152.14%.
View full InMed Pharmaceuticals company overviewInMed Pharmaceuticals free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2024 | 2024-06-30 | −$7.0M | $448,088 | — | −152.14% |
| 2023 | 2023-06-30 | −$7.4M | $8.2M | — | −544.99% |
| 2022 | 2022-06-30 | −$15.6M | −$5.8M | — | −1143.90% |
| 2021 | 2021-06-30 | −$9.8M | −$2.4M | — | −514.30% |
| 2020 | 2020-06-30 | −$7.4M | — | — | — |
InMed Pharmaceuticals quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q3 2024 | 2024-03-31 | −$1.9M | — | — | −164.96% |
| Q4 2022 | 2022-06-30 | −$4.0M | — | — | — |
| Q3 2022 | 2022-03-31 | −$5.4M | — | — | −1728.88% |
| Q2 2022 | 2021-12-31 | −$3.7M | — | — | −1413.94% |
| Q1 2022 | 2021-09-30 | −$2.9M | — | — | — |
| Q4 2020 | 2020-06-30 | −$1.4M | — | — | — |
| Q3 2020 | 2020-03-31 | −$1.5M | — | — | — |
| Q2 2020 | 2019-12-31 | −$2.1M | — | — | — |
| Q1 2020 | 2019-09-30 | −$2.4M | — | — | — |
InMed Pharmaceuticals free cash flow growth trends
InMed Pharmaceuticals's latest reported quarter, Q3 2024, generated −$1.9M in free cash flow.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review InMed Pharmaceuticals source filings ↗